Incidence and severity of primary graft dysfunction after lung transplantation using rejected grafts reconditioned with ex vivo lung perfusion†

Incidence and severity of primary graft dysfunction after lung transplantation using rejected grafts reconditioned with ex vivo lung perfusion.

OBJECTIVES Ex vivo lung perfusion (EVLP) is a novel technique used to evaluate and recondition marginal or rejected grafts. Primary graft dysfunction (PGD) is a major early complication after lung transplantation (LTx). The use of marginal or initially rejected grafts may increase its incidence and severity. The aim of this study is to evaluate the incidence of PGD after LTx using rejected graf...

Primary Graft Dysfunction After Lung Transplantation.

Primary graft dysfunction is a form of acute injury after lung transplantation that is associated with significant short- and long-term morbidity and mortality. Multiple mechanisms contribute to the pathogenesis of primary graft dysfunction, including ischemia reperfusion injury, epithelial cell death, endothelial cell dysfunction, innate immune activation, oxidative stress, and release of infl...

Long Term Impact of Primary Graft Dysfunction after Lung Transplantation

According to the International Society for Heart and Lung Transplantation (ISHLT) Registry, graft failure accounted for 24.7% of deaths within 30 days of transplantation among adult lung recipients between 1992 and 2012 [1]. Although important details distinguishing different causes of early graft failure may be missing from the Registry data, it is likely that primary graft dysfunction (PGD) i...

New perspectives in lung transplantation: from conventional preservation to ex vivo lung perfusion and lung reconditioning.

Aprotinin in lung transplantation is associated with an increased incidence of primary graft dysfunction.

OBJECTIVE Aprotinin has been widely used to reduce bleeding and transfusion requirements in cardiac surgery and in lung transplantation. A recent study found a significant reduction in severe (grade III) primary graft dysfunction (PGD) in lung transplantation where aprotinin had been used. However, recently, concerns regarding the safety of aprotinin have been raised, and the future use of apro...